ANDA 217884, held by Fresenius Kabi USA. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 217884 (Succinylcholine Chloride), held by Fresenius Kabi USA, was first approved by FDA on Feb 11, 2025, with 0 approved supplements and 0 published complete response letters.
Succinylcholine Chloride Injection is indicated in adults and pediatric patients: as an adjunct to general anesthesia to facilitate tracheal intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride100MG/5ML (20MG/ML) · solution;intramuscular, intravenous | Succinylcholine Chloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters